Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-α in patients with chronic hepatitis C

Croatian Medical Journal

Volumn 48, Issue 6, 2007, Pages 807-813

  Ivić, Ivo ^a   Bradarić, Nikola ^a   Puizina Ivić, Neira ^a   Ledina, Dragan ^a   Lukšič, Boris ^a   Martinić, Roko ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; HLA CW7 ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; HLA ANTIGEN;

ADULT; ALLELE; ARTICLE; CROATIA; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; TREATMENT RESPONSE; BLOOD; GENETICS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ALLELES; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HLA ANTIGENS; HUMANS; INTERFERON-ALPHA; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 38449084178     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2007.6.807     Document Type: Article

References (30)

1. Chang KM. The mechanisms of chronicity in hepatitis C virus infection. Gastroenterology. 1998;115:1015-8. doi:10.1016/S0016-5085(98)70277-X
2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.
3. Marušić M, Kovač Z. Immunopathophysiology: immunopathogenetic role of HLA. In: Gamulin S, Marušić M, Kovač Z, editors. Pathophysiology. Zagreb: Medicinska naklada; 2002. p. 430-5.
4. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol. 2000;30:2479-87. doi:10.1002/1521-4141(200009)30:9〈2479::AIDIMMU2479〉3.0.CO;2-B
5. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis. 2003;7:89-105. doi:10.1016/S1089-3261(02)00068-5
6. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol. 2007;13:1770-87.
7. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 1997;112:1017-21. doi:10.1053/gast.1997.v112.pm9041265
8. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA, et al. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology. 2003;37:1180-8. doi:10.1053/jhep.2003.50184
9. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology. 1996;23:909-16. doi:10.1002/hep.510230436
10. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology. 1991;183:1-11. doi:10.1016/0042-6822(91)90112-O
11. Löhr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Büschenfelde KH. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol. 1999;31:407-15. doi:10.1016/S0168-8278(99)80030-0
12. Miyaguchi S, Saito H, Ebinuma H, Morizane T, Ishii H. Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C. Tissue Antigens. 1997;49:605-11.
13. Romero-Gómez M, González-Escribano MF, Torres B, Barroso N, Montes-Cano MA, Sánchez-Muńoz D, et al. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2003;98:1621-6.
14. Vucelić B, Hrstić I, Begovac J, Bradarić N, Burek V, Čolić-Cvrlje V, et al. Viral hepatitis: Croatian consensus statement [in Croatian]. Acta Med Croatica. 2005;5:359-75.
15. Hennig H, Schlenke P, Kirchner H, Bauer I, Schulte-Kellinghaus B, Bludau H. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods. 2000;84:181-90. doi:10.1016/S0166-0934(99)00146-9
16. Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 1993;31:882-6.
17. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol. 1999;31 Suppl 1:54-60. doi:10.1016/S0168-8278(99)80375-4
18. Saldanha J, Lelie N, Heath A, WHO collaborative study group. Establishment of the first international standards for nucleic acid amplification technology (NAT) assays for HCV RNA. Wox Sang. 1999;76:149-58. doi:10.1159/000031040
19. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol. 1996;34:2259-66.
20. Čečuk-Jeličić E, Grubič Z, Štingl K, Žunec R, Brkljačić-Kehirn V. HLA-A and -B frequencies in a population from Croatia. Hum Immunol. 2004;65:912-6. doi:10.1016/j.humimm.2004.08.032
21. Čečuk-Jeličić E, Grubić Z, Brkljačić-Kehirn V, Kaštelan M, Kaštelan A. Comparison of serology and DNA methods for HLA-Cw typing in the Croatian population. Period Biol. 1999;101:71-5.
22. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5. doi:10.1002/hep.1840010511
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93. doi:10.1002/hep.510240201
24. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol. 2002;76:4792-7. doi:10.1128/JVI.76.10.4792-4797.2002
25. Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology. 2006;43:241-9. doi:10.1002/hep.21040
26. Martinetti M, Pacati I, Cuccia M, Badulli C, Pasi A, Salvaneschi L, et al. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol. 2006;19:369-78.
27. Shiina M, Kobayashi K, Kobayashi T, Kondo Y, Ueno Y, Shimosegawa T. Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients. J Gastroenterol. 2006;41:758-64. doi:10.1007/s00535-006-1843-9
28. Freni MA, Ajello A, Spadaro A, Fava A, Calapristi I, Marafioti T, et al. Class I HLA antigens hepatic display and beta-2-microglobulin serum values in chronic hepatitis C: effect of treatment with recombinant alpha interferon. Hepatogastroenterology. 1997;44:1295-301.
29. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol. 2007;149:1-8.
30. Rauch A, Laird R, McKinnon E, Telenti A, Furrer H, Weber R, et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens. 2007;69 Suppl 1:237-40. doi:10.1111/j.1399-0039.2006.773_4.x